Оцінка економічної доступності схем антинеопластичної терапії хворих на рак молочної залози

Abstract

In the article the results of evaluation of the economic availability of the standard treatment regimens of patients with breast cancer are highlighted. It found, that almost all schemes of antineoplastic therapy in patients with breast cancer, that formed with trade names of drugs with minimum, average and maximum cost of course dose were low available for Ukrainian patients. Only two schemes: SMF (cyclophosphamide + methotrexate + fluorouracyl) and AC (doxorubicin + cyclophosphamide), solvency adequacy rates of which were respectively 12.12% and 14.8%, were average available for Ukrainian patients. The problem of low economic availability of anticancer therapy of breast cancer leads to the need for government to organize reimbursement programs (partial or full) cost of therapy, to implement of health insurance, and to implement effective mechanisms for prevention of the disease and methods of early diagnosis.